Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study

Phyo Pyae Nyein; Kathy Petoumenos; Margaret Borok; Nnakelu Eriobu; Nagalingeswaran Kumarasamy; Anchalee Avihingsanon; Iskandar Azwa; Sounkalo Dao; Mohamed Cisse; Nila J Dharan; Josh Hanson; Gail V Matthews

doi:10.1093/cid/ciae256

Associations between antiretroviral regimen and changes in blood pressure: results from the D2EFT study

Clin Infect Dis. 2024 May 9:ciae256. doi: 10.1093/cid/ciae256. Online ahead of print.

Affiliations

¹ The Kirby Institute, University of New South Wales, Australia.
² University of Zimbabwe Clinical Research Centre, Zimbabwe.
³ Institue of Human Virology Nigeria, Nigeria.
⁴ Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS) Voluntary Health Services (VHS), India.
⁵ The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research Centre, Thailand.
⁶ University of Malaya Medical Centre (UMMC), Malaysia.
⁷ University Clinical Research Centre (UCRC), Mali.
⁸ Centre de traitement ambulatoire de Donka (Hospital de jour), Guinea.

PMID: 38721980
DOI: 10.1093/cid/ciae256

Abstract

In this randomised, controlled study in 14 low- and middle-income countries, individuals taking dolutegravir with darunavir/ritonavir for 48 weeks had a greater increase in systolic and diastolic blood pressure than individuals taking two nucleoside reverse transcriptase with darunavir/ritonavir. The difference remained significant after controlling for confounding factors including weight gain.

Keywords: HIV; cardiovascular risk; dolutegravir; hypertension; low- and middle-income countries.

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].